ciated with the use of vancomycin is believed to be due to a hypersensitivity reaction, since antineutrophil antibodies have been discovered in the serum of some patients. 4 These The occurrence of hematologic side-effects resulting from the use of vancomycin is rare. Prior to this report, antibodies bind to the circulating neutrophils, resulting in sequestration and phagocytosis of the opsonized neutrophils vancomycin-induced neutropenia was believed to be due to a hypersensitivity reaction since antibodies directed by splenic macrophages. Vancomycin-induced agranulocytosis has also been described. 5 Antibiotics other than vanagainst circulating neutrophils have been discovered in the serum of some patients. We demonstrate supcomycin, especially the ␤-lactam antibiotics, demonstrate suppression of progenitor cell growth in vivo and in vitro. Patients undergoing autologous hematopoietic stem cell specimen obtained at the time of neutropenia demonstrated direct suppression of progenitor cell growth in transplantation develop severe and sometimes protracted pancytopenia resulting from the myeloablative induction vitro when vancomycin was added at increasing concentrations (1, 10 and 50 g/ml). No such trend was noted regimen. Due to the use of indwelling central venous catheters in the majority of these patients and the widespread in a BM sample from the same patient obtained 11 months prior to transplantation and a normal control use of empiric gram-negative antibiotic coverage, the most common pathogens causing bacteremia in this patient popu-BM. The decrease in the total number of colony-forming units (CFU) was statistically significant at all the dose lation are gram-positive organisms. 8 Although the optimal empiric treatment for febrile neutropenia is controversial, levels of vancomycin when compared to the number of CFU in the baseline BM sample (P Ͻ 0.05). The myeloid vancomycin is commonly used in combination with cephalosporins or aminoglycosides. Attal et al 9 reported a maturation arrest observed in the bone marrow sample obtained during the period of neutropenia and the dose reduction in the number of gram-positive infections in patients receiving prophylactic vancomycin after bone mardependent growth inhibition by vancomycin observed in vitro suggest a novel nonimmune mechanism of hemarow transplantation (BMT) with a significant decrease in morbidity. tologic effects due to suppression of bone marrow progenitor cell growth.
Patients undergoing autologous hematopoietic stem cell specimen obtained at the time of neutropenia demonstrated direct suppression of progenitor cell growth in transplantation develop severe and sometimes protracted pancytopenia resulting from the myeloablative induction vitro when vancomycin was added at increasing concentrations (1, 10 and 50 g/ml). No such trend was noted regimen. Due to the use of indwelling central venous catheters in the majority of these patients and the widespread in a BM sample from the same patient obtained 11 months prior to transplantation and a normal control use of empiric gram-negative antibiotic coverage, the most common pathogens causing bacteremia in this patient popu-BM. The decrease in the total number of colony-forming units (CFU) was statistically significant at all the dose lation are gram-positive organisms. 8 Although the optimal empiric treatment for febrile neutropenia is controversial, levels of vancomycin when compared to the number of CFU in the baseline BM sample (P Ͻ 0.05). The myeloid vancomycin is commonly used in combination with cephalosporins or aminoglycosides. Attal et al 9 reported a maturation arrest observed in the bone marrow sample obtained during the period of neutropenia and the dose reduction in the number of gram-positive infections in patients receiving prophylactic vancomycin after bone mardependent growth inhibition by vancomycin observed in vitro suggest a novel nonimmune mechanism of hemarow transplantation (BMT) with a significant decrease in morbidity. tologic effects due to suppression of bone marrow progenitor cell growth.
We describe a patient who developed neutropenia associated with the use of vancomycin after receiving an autoKeywords: vancomycin; drug-induced neutropenia; autologous stem cell transplantation; multiple myeloma logous peripheral blood stem cell (PBSC) and bone marrow (BM) transplantation for multiple myeloma (MM). We evaluated the in vitro effects of vancomycin on the patient's bone marrow progenitor cell growth. These results propose Vancomycin can adversely affect the growth and developan alternative mechanism of vancomycin-induced effects ment of erythroid, myeloid and platelet cell lines. Vancoon hematopoiesis. mycin may bind directly to the membrane of red blood cells resulting in red blood cell aggregation or may result in the development of platelet-associated immunoglobulin, sugMethods gesting an autoimmune mechanism.
1-3 Neutropenia asso-Georgetown University Medical Center clinical trial, the patient received autologous BM and PBSC that were cultured in interleukin-2 (IL-2) for 24 h prior to reinfusion. [10] [11] [12] During the transplantation course, an episode of bacteremia was treated with intravenous vancomycin, ciprofloxacin and ceftazidime for 14 days. The dose of vancomycin was adjusted based on serum levels and the serum creatinine remained within the normal range. The patient was also treated with oral vancomycin for pseudomembranous colitis. Parenteral IL-2 was not administered during the transplant course and the patient did not receive growth factor support. The absolute neutrophil count (ANC) reached 0.5 × 10 9 /l on day 10 and an untransfused platelet level of 20 × 10 9 /l was reached on day 17. The patient improved clinically, was blood product transfusion 2.4 × 10 9 /l (58% neutrophils, 5% bands, 21% lymphocytes, (---) and absolute neutrophil count (ANC) (--).
15% monocytes, and 1% atypical lymphocytes), a hematocrit of 26.5%, and platelet count of 22 × 10 9 /l. biopsy revealed 20% cellularity with trilineage maturation. The patient was readmitted to the hospital within 2 days There were focal islands of plasma cells comprising less after discharge with a temperature of 39°C, a WBC of than 3% of the bone marrow population. 1.8 × 10 9 /l and an ANC of 1.1 × 10 9 /l, a stable hemoglobin and a platelet count of 12 × 10 9 /l. No localizing signs or symptoms of an infectious process were present and the Methods physical examination was normal. Ceftazidime and vancomycin (1 g i.v. every 12 h) were initiated. Within 24 h of Clonogenic colony growth and assessment initiating antibiotics, the WBC dropped to 0.5 × 10 9 /l despite an unremarkable clinical course and rhG-CSF supThe patient's previously harvested bone marrow (obtained port was initiated. 13 The patient's temperature resolved 11 months prior to transplantation) and bone marrow within 36 h after admission. Bacterial and viral cultures obtained during the period of neutropenia were plated in from the blood, urine and throat were negative. Serum parduplicate at a concentration of 1 × 10 5 cells/ml in semisolid vovirus B-19 immunoglobulin titers were negative and methyl cellulose medium (StemCell Technologies, Van-PCR analysis of the blood for parvovirus B-19 and cytomecouver, Canada) supplemented with GM-CSF (20 g/ml) galovirus (CMV) were negative. Hepatitis serologies were and erythropoietin (2 U/ml). A control bone marrow sample negative. Due to the persistence of pancytopenia, a bone from a normal donor was plated simultaneously. The three marrow biopsy was obtained 8 days after admission and bone marrow specimens were processed by density centrirevealed 2% cellularity with rare myeloid precursors, evifugation on Ficol-Hypaque 1077 to obtain the mononuclear dence of erythroid hyperplasia with a myeloid:erythroid cells. Mononuclear cells (1 × 10 5 ) were plated from each (M:E) ratio of 1:10 and an adequate number of megakaryof the three bone marrow specimens. Vancomycin was ocytes. Immunohistochemistry revealed clonally restricted added at increasing concentrations: 1 g/ml, 10 g/ml and plasma cells consistent with the original paraprotein (IgG 50 g/ml to each of the specimens (Table 1) . Duplicate ) and PCR demonstrated the persistence of a rearranged immunoglobulin consistent with residual disease. Since the WBC increased to 1.2 × 10 9 /l and stabilized at 3.6-4 × 10 9 /l 50 g/ml Ͻ0.02 17.0 ± 2.1 134 ± 2.1 256 ± 6.1 within 5 days (Figure 1) . A bone marrow biopsy performed 7 days after discontinuation of vancomycin revealed 40%
Note: The numbers reported are the mean ± standard error of the mean cellularity with mild myeloid hyperplasia with an M:E ratio for total colonies from duplicate cultures.
of 4-5:1, orderly myeloid maturation, and an adequate
The P values compare the number of progenitor cells in the current BM to the baseline culture. The Student's t-test was used to determine P values.
number of megakaryocytes.
Therapeutic serum levels of vancomycin: 10-40 g/ml.
The patient's course was complicated by progressive
Colony growth of all mononuclear bone marrow cells (including CFUliver insufficiency and gastrointestinal bleeding requiring GM, BFU-E and CFU-GEMM) analyzed after 14 days in culture. Cells multiple platelet and RBC transfusions. The patient died were cultured at 1 × 10cultures of 1 ml were performed in 35 mm Petri dishes. (15.6 × 10 8 MNC/kg) and evidence of clonogenic progenitor cell growth in the BM and PBSC graft. Any obvious These were incubated for 14 days at 37°C in a humidified atmosphere of 5% CO 2 . On day 14, the total number of source of infection was not evident during the patient's hospital course. Numerous cultures and serologies were colonies (CFU-GM, BFU-E and CFU-GEMM) were enumerated using an inverted microscope. Clusters of 40 or obtained and revealed no evidence of infection. There were no clinical findings to suspect autologous GVHD. IL-2 actimore cells were counted as colonies.
vation of autologous stem cells does not affect the growth and development of hematopoietic progenitor cells. 14,15 The Interleukin-2 activation of PBSC and the induction results of the bone marrow biopsy demonstrating 2% celluregimen larity (considering the time point after transplantation) without myeloid maturation appeared consistent with an The process of culturing autologous hematopoietic stem cells with IL-2 for 24 h has been described previously. 14 acute 'toxic' event. Although there was phenotypic evidence of persistent multiple myeloma in the bone marrow Briefly, one day prior to PBSC and BM infusion, the harvested BM and PBSC were thawed. IL-2 was added at 6000 obtained during the period of neutropenia, the minor clonal population could not account for the degree of neutropenia. IU/ml to the thawed cell suspensions. Incubation for 24 h occurred in X-vivo serum free medium (BioWhittaker, As a result, all medications was discontinued, except for vancomycin. Despite these measures, the neutropenia perWalkersville, MD, USA) containing gentamicin (50 g/ml), l-glutamine (50 g/ml) and heparin with benzyl sisted. Since vancomycin-induced neutropenia has been previously reported, the vancomycin was changed to nafcilalcohol (1%) as a preservative (Elkins-Simm, Cherry Hill, NJ, USA).
lin. 7,16,17 While remaining on nafcillin and within 24 h of discontinuing vancomycin, the patient's WBC and the ANC After high-dose chemotherapy with cyclophosphamide and busulfan, the activated PBSC and BM were infused. improved markedly. This patient's clinical course is consistent with other rare cases reported in the literature of vancomycin-induced neutropenia, although no case has been reported in a transResults planted patient. 4, 16, 18 Typically, the WBC counts drop suddenly after 2 weeks of vancomycin therapy and may The colony growth of all bone marrow mononuclear cells was analyzed after 14 days in culture. The patient's BM recover rapidly, within 2 to 3 days of removal of the drug, sometimes even within 24 h. 19 In addition, the neutrophil obtained during the period of neutropenia and the previously harvested BM demonstrated a lower number of count may rise rapidly once vancomycin is discontinued, despite continuation of a penicillin-type drug. 20 The patient mononuclear cells (75.5 ± 4.6 × 10 5 and 133 ± 11.4 × 10 5 respectively) when compared to the control BM we report had received vancomycin for 14 days in the immediate past during her hospitalization for transplan-(253.5 ± 3.5 × 10 5 ). With the addition of increasing concentrations of vancomycin, the patient's current BM demontation. Upon re-exposure to vancomycin, there was a rapid drop in WBC followed by a rapid rise once the vancomycin strated suppression of progenitor cell growth, without significant change in the growth of colonies in the control BM was discontinued. 4 The development of neutropenia associated with vancospecimen or the patient's previously harvested BM ( Table  1 ). The range of concentrations of vancomycin added to the mycin is presumed to be due to an autoimmune reaction, since vancomycin-dependent antibodies to patients' neutroin vitro cultures (0-50 g/ml) encompassed the therapeutic levels achieved in vivo (10-40 g/ml).
phils have been discovered on rare occasions. 4 Suppression of bone marrow progenitor cell growth by vancomycin has not been described previously in the transplant setting.
Reports in the literature demonstrate that BM biopsies perDiscussion formed on five patients experiencing vancomycin-induced neutropenia showed either myeloid hyperplasia or normal We report the first case of reversible neutropenia associated with vancomycin after autologous PBSC and BM transplanmyeloid development. 4, 17, 21 Our in vitro results demonstrate inhibition of cell growth, with the myeloid line being affectation in a patient with MM. The in vitro culture results suggest direct suppression of myeloid progenitor cell ted the most, suggesting direct suppression of progenitor cell growth. Immune-mediated mechanisms, such as an growth when vancomycin was added to the culture, an event not previously described.
antibody-mediated response, cannot be explained by our findings since humoral effects, such as antineutrophil antiThe abrupt onset of neutropenia in a patient after successful engraftment following autologous stem cell transbodies, are absent in an in vitro culture. In addition, an antibody-directed immune response would not result in a plantation may be due to various causes, including qualitative and quantitative abnormalities of the stem cells, dose-dependent inhibition of bone marrow progenitor cell growth. Alternative possibilities include a direct toxic effect autoimmune processes, infections, toxins or medications. In addition, we have observed a decrease in platelet counts in obtained during the first exposure to vancomycin, making the hematopoietic progenitors susceptible to the drug with patients receiving this treatment regimen with IL-2 activated autologous stem cells, possibly the result of autologovert effects observed only after re-exposure. A second possibility includes a cytotoxic T cell-mediated response; ous graft versus host disease (GVHD).
11 When these areas were evaluated in our patient, we found adequate numbers the first exposure to vancomycin may have led to the induction of cytotoxic cells and the subsequent exposure to vanof CD34 + cells (2.4 × 10 6 cells/kg), total mononuclear cells 
